Skip to main content

Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Publication ,  Journal Article
Crawford, J; Becker, PS; Armitage, JO; Blayney, DW; Chavez, J; Curtin, P; Dinner, S; Fynan, T; Gojo, I; Griffiths, EA; Hough, S; Kloth, DD ...
Published in: J Natl Compr Canc Netw
December 2017

Myeloid growth factors (MGFs) are given as supportive care to patients receiving myelosuppressive chemotherapy to reduce the incidence of neutropenia. This selection from the NCCN Guidelines for MGFs focuses on the evaluation of regimen- and patient-specific risk factors for the development of febrile neutropenia (FN), the prophylactic use of MGFs for the prevention of chemotherapy-induced FN, and assessing the risks and benefits of MGF use in clinical practice.

Duke Scholars

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

December 2017

Volume

15

Issue

12

Start / End Page

1520 / 1541

Location

United States

Related Subject Headings

  • Risk Factors
  • Oncology & Carcinogenesis
  • Neoplasms
  • Myeloid Cells
  • Medical Oncology
  • Intercellular Signaling Peptides and Proteins
  • Incidence
  • Humans
  • Chemotherapy-Induced Febrile Neutropenia
  • Antineoplastic Agents
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Crawford, J., Becker, P. S., Armitage, J. O., Blayney, D. W., Chavez, J., Curtin, P., … Pluchino, L. (2017). Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 15(12), 1520–1541. https://doi.org/10.6004/jnccn.2017.0175
Crawford, Jeffrey, Pamela Sue Becker, James O. Armitage, Douglas W. Blayney, Julio Chavez, Peter Curtin, Shira Dinner, et al. “Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw 15, no. 12 (December 2017): 1520–41. https://doi.org/10.6004/jnccn.2017.0175.
Crawford J, Becker PS, Armitage JO, Blayney DW, Chavez J, Curtin P, et al. Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Dec;15(12):1520–41.
Crawford, Jeffrey, et al. “Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.J Natl Compr Canc Netw, vol. 15, no. 12, Dec. 2017, pp. 1520–41. Pubmed, doi:10.6004/jnccn.2017.0175.
Crawford J, Becker PS, Armitage JO, Blayney DW, Chavez J, Curtin P, Dinner S, Fynan T, Gojo I, Griffiths EA, Hough S, Kloth DD, Kuter DJ, Lyman GH, Mably M, Mukherjee S, Patel S, Perez LE, Poust A, Rampal R, Roy V, Rugo HS, Saad AA, Schwartzberg LS, Shayani S, Talbott M, Vadhan-Raj S, Vasu S, Wadleigh M, Westervelt P, Burns JL, Pluchino L. Myeloid Growth Factors, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017 Dec;15(12):1520–1541.

Published In

J Natl Compr Canc Netw

DOI

EISSN

1540-1413

Publication Date

December 2017

Volume

15

Issue

12

Start / End Page

1520 / 1541

Location

United States

Related Subject Headings

  • Risk Factors
  • Oncology & Carcinogenesis
  • Neoplasms
  • Myeloid Cells
  • Medical Oncology
  • Intercellular Signaling Peptides and Proteins
  • Incidence
  • Humans
  • Chemotherapy-Induced Febrile Neutropenia
  • Antineoplastic Agents